Skip to content

Aerobic Exercise in Women With Gestational Diabetes

Efficacy of Supervised Physical Exercise in Metabolic Control of Women With Gestational Diabetes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03067662
Acronym
GDM-FIT
Enrollment
48
Registered
2017-03-01
Start date
2012-09-27
Completion date
2022-12-30
Last updated
2021-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes Mellitus in Pregnancy

Brief summary

A few, small randomized controlled trials have investigated the effects of exercise on blood glucose levels in women with gestational diabetes (GDM), with inconsistent results. To assess the effects of supervised exercise in women with GDM, 48 women with gestational diabetes, diagnosed between the 18th and 28th week of gestation, will be recruited, after exclusion of subjects with contraindications to exercise. These subjects will be randomly assigned to two groups: structured exercise intervention or standard care. Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (heart rate reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (increasing 2 min/week). Women in the control group will receive standard diet and physical exercise recommendations. In all women, clinical, metabolic and anthropometric features will be assessed before, during and at the end of the study. Newborn data will also be collected.

Interventions

OTHERAerobic exercise

Sponsors

Universita di Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Singleton pregnancy, * Gestational diabetes diagnosis between 18th and 28th week of gestation, * Caucasian.

Exclusion criteria

* Hemodynamically significant heart disease, * Restricted lung disease, * Incompetent cervix/cerclage, * Persistent second or third trimester bleeding, * Placenta previa, * Threatened preterm labor, * Ruptured membranes, * Preeclampsia, * Hypertension, * Severe anemia, * Cardiac arrhythmias, * History of epilepsy, * Chronic bronchitis, * Orthopedic limitations, * Overt hyperthyroidism/ hypothyroidism, * Type 1 diabetes mellitus, * Drugs that interfere with metabolic control (such as cortisone)

Design outcomes

Primary

MeasureTime frame
Change in fasting plasma glucose levels (mg/dL)Before intervention and at 35-37 week of gestation

Secondary

MeasureTime frameDescription
Change in body mass index (kg/m^2, weight in kilograms, height in meters)Before intervention and at 35-37 week of gestation
Change in blood pressure (mmHg)Before intervention and at 35-37 week of gestation
Change in heart rate (HR, beats per minute)Before intervention and at 35-37 week of gestation
Dosage of insulin therapy, if requiredBefore intervention and at 35-37 week of gestationInsulin units and week at start
Change in caloric intakeBefore intervention and at 35-37 week of gestationBy 3 day-food recall questionnaire (kcal/die)
Change in energy expenditure through voluntary physical activityBefore intervention and at 35-37 week of gestationEnergy expenditure is estimated by International Physical Activity Questionnaire (IPAQ)
Compliance (percentage)Throughout the intervention period, an average of 3-5 months according to the gestational week of inclusion in the studyAttendance at the scheduled sessions is recorded for each patient
Circulating c-reactive protein (CRP) levels (mg/dL)Before intervention and at 35-37 week of gestation
Adiponectin levels (μg/mL)Before intervention and at 35-37 week of gestation
Pulse wave velocity (PWV, m/s)Before intervention and at 35-37 week of gestationA non-invasive assessment of arterial stiffness (in the carotid-radial and carotid-femoral parts of the arterial tree) by the technique of applanation tonometry
Quality of life (questionnaire)Before intervention and at 35-37 week of gestationMeasured by SF-36 (36-item Short Form Health Survey-36) questionnaire
Depression state (questionnaire)Before intervention and at 35-37 week of gestationMeasured by Center of Epidemiological Studies Depression Scale
Glucose concentration during and after exerciseAt 32-34 week of gestationA continuous glucose monitoring system (CGMS) will be applied at 32-34 week of gestation, and blood glucose will be recorded every 5 min over the following five days. Glucose concentrations during the 40-min exercise session, the subsequent night, and the 24-h period following exercise, as well as during the corresponding periods of a non-exercise day will be recorded, and glucose variability and time spent in hypoglycemia or hyperglycemia will be calculated
Change in body weight (kg)Before intervention and at 35-37 week of gestation
Fetus head circumference (cm)At 20, 30, 34-37 week of gestation
Fetus abdominal circumference (cm)At 20, 30, 34-37 week of gestation
Fetus femur length (cm)At 20, 30, 34-37 week of gestation
Weight (kg) of child at birth3 months after delivery
Length (cm) of child at birth3 months after delivery
Apgar index (score) at 1st and 5th minutesBirthday
Gender (M/F)3 months after delivery
Malformations and neonatal diseases (YES/NO)3 months after delivery
Type of delivery (spontaneous, induced, caesarean section)3 months after delivery
Week of delivery (wk)3 months after delivery
Type of feeding (breastfeeding or bottle feeding)3 months after delivery
Weight (kg) of child 3 months after delivery3 months after delivery
Length (cm) of child 3 months after delivery3 months after delivery
Fetus bi-parietal diameter (cm)At 20, 30, 34-37 week of gestation

Countries

Italy

Contacts

Primary ContactPaolo Moghetti, MD, PhD
paolo.moghetti@univr.it
Backup ContactSilvia Donà, MSC
silvia.dona@univr.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026